B. Peterson

Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy.

E. Lengyel, D. Catenacci, Y. Tan, 2020, JCO precision oncology.

Pancreatic β-Cell Adaptive Plasticity in Obesity Increases Insulin Production but Adversely Affects Secretory Function

B. Marsh, P. Arvan, A. Noske, 2015, Diabetes.

Evaluation of spatiotemporal heterogeneity of tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy.

Katherine I Zhou, D. Catenacci, Anthony V. Serritella, 2020 .

Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease.

Leah M Chase, U. Siddiqui, M. Posner, 2020, Cancer discovery.

Morphologic and molecular analysis of early‐onset gastric cancer

S. Shroff, J. Misdraji, J. Hart, 2020, Cancer.

Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy

Katherine I Zhou, D. Catenacci, Anthony V. Serritella, 2020, Clinical Cancer Research.

Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience

Y. Janjigian, G. Ku, Z. Wainberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.

Leah M Chase, U. Siddiqui, M. Posner, 2020, JAMA network open.

Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).

Leah M Chase, U. Siddiqui, M. Posner, 2020 .